MARKSANS PHARMA
Quarterly Results Analysis [Sep2024]
MARKSANS PHARMA Quarterly Results
Consolidated | Sep2024 UnAudited |
Jun2024 UnAudited |
Mar2024 UnAudited |
Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
Mar2023 Audited |
Dec2022 UnAudited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹642 Cr | ₹591 Cr | ₹560 Cr | ₹586 Cr | ₹531 Cr | ₹500 Cr | ₹486 Cr | ₹480 Cr |
Expenses | ₹506 Cr | ₹462 Cr | ₹450 Cr | ₹453 Cr | ₹417 Cr | ₹398 Cr | ₹376 Cr | ₹403 Cr |
Operating Income | ₹136 Cr | ₹128 Cr | ₹110 Cr | ₹133 Cr | ₹114 Cr | ₹102 Cr | ₹110 Cr | ₹77 Cr |
Other Income | ₹11 Cr | ₹15 Cr | ₹17 Cr | ₹5 Cr | ₹19 Cr | ₹10 Cr | ₹11 Cr | ₹18 Cr |
Interest | ₹3 Cr | ₹3 Cr | ₹5 Cr | ₹3 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr |
Depreciation | ₹20 Cr | ₹20 Cr | ₹21 Cr | ₹22 Cr | ₹18 Cr | ₹14 Cr | ₹14 Cr | ₹13 Cr |
Profit Before Tax | ₹125 Cr | ₹120 Cr | ₹100 Cr | ₹113 Cr | ₹114 Cr | ₹97 Cr | ₹104 Cr | ₹79 Cr |
Profit After Tax | ₹98 Cr | ₹89 Cr | ₹78 Cr | ₹83 Cr | ₹84 Cr | ₹70 Cr | ₹83 Cr | ₹62 Cr |
EPS | ₹2.13 | ₹1.96 | ₹1.73 | ₹1.84 | ₹1.84 | ₹1.52 | ₹1.81 | ₹1.57 |
Industry Peers & Returns | 1W | 1M | 1Y |
MARKSANS PHARMA | 1.5% | -14.7% | 89.4% |
SUN PHARMACEUTICAL INDUSTRIES | 0.9% | 4.4% | 50% |
CIPLA | 2.1% | 0.2% | 22.8% |
DR REDDYS LABORATORIES | -1.1% | 12.1% | 18.1% |
ZYDUS LIFESCIENCES | 1.8% | 0.9% | 41.3% |
DIVIS LABORATORIES | 4.6% | -1.1% | 55.6% |
MANKIND PHARMA | 0.9% | 13.3% | 45.6% |
TORRENT PHARMACEUTICALS | 1.2% | 2.5% | 48.2% |
LUPIN | 7.6% | 15.1% | 78.8% |
MARKSANS PHARMA Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | 8.69 % |
Y-o-Y | 20.84 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Sep2024 | ₹642 Cr | 8.69 | |
Jun2024 | ₹591 Cr | 5.47 | |
Mar2024 | ₹560 Cr | -4.46 | |
Dec2023 | ₹586 Cr | 10.33 | |
Sep2023 | ₹531 Cr | 6.24 | |
Jun2023 | ₹500 Cr | 2.89 | |
Mar2023 | ₹486 Cr | 1.28 | |
Dec2022 | ₹480 Cr | - |
MARKSANS PHARMA Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | 5.64 % |
Y-o-Y | 19.07 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Sep2024 | ₹136 Cr | 5.64 | |
Jun2024 | ₹128 Cr | 17.14 | |
Mar2024 | ₹110 Cr | -17.58 | |
Dec2023 | ₹133 Cr | 16.74 | |
Sep2023 | ₹114 Cr | 11.75 | |
Jun2023 | ₹102 Cr | -6.92 | |
Mar2023 | ₹110 Cr | 42.93 | |
Dec2022 | ₹77 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | -2.80 % |
Y-o-Y | -1.45 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Sep2024 | 21.14% | -2.80 | |
Jun2024 | 21.75% | 11.08 | |
Mar2024 | 19.58% | -13.74 | |
Dec2023 | 22.7% | 5.83 | |
Sep2023 | 21.45% | 5.20 | |
Jun2023 | 20.39% | -9.54 | |
Mar2023 | 22.54% | 41.14 | |
Dec2022 | 15.97% | - |
MARKSANS PHARMA Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | 9.76 % |
Y-o-Y | 16.59 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Sep2024 | ₹98 Cr | 9.76 | |
Jun2024 | ₹89 Cr | 14.71 | |
Mar2024 | ₹78 Cr | -6.41 | |
Dec2023 | ₹83 Cr | -1.06 | |
Sep2023 | ₹84 Cr | 19.04 | |
Jun2023 | ₹70 Cr | -14.84 | |
Mar2023 | ₹83 Cr | 32.75 | |
Dec2022 | ₹62 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | 0.99 % |
Y-o-Y | -3.49 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Sep2024 | 15.23 % | 0.99 | |
Jun2024 | 15.08 % | 8.80 | |
Mar2024 | 13.86 % | -2.05 | |
Dec2023 | 14.15 % | -10.33 | |
Sep2023 | 15.78 % | 11.99 | |
Jun2023 | 14.09 % | -17.22 | |
Mar2023 | 17.02 % | 31.02 | |
Dec2022 | 12.99 % | - |
MARKSANS PHARMA Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | 8.67 % |
Y-o-Y | 15.76 % |
Quarters | EPS | % Change | |
---|---|---|---|
Sep2024 | ₹2.13 | 8.67 | |
Jun2024 | ₹1.96 | 13.29 | |
Mar2024 | ₹1.73 | -5.98 | |
Dec2023 | ₹1.84 | 0.00 | |
Sep2023 | ₹1.84 | 21.05 | |
Jun2023 | ₹1.52 | -16.02 | |
Mar2023 | ₹1.81 | 15.29 | |
Dec2022 | ₹1.57 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs MANKIND PHARMA LTD